NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics Q4 Revenue Surge Tests Bulls’ Profitability Narrative
Axsome Therapeutics (AXSM) closed FY 2025 with Q4 revenue of US$196.0 million and a basic EPS loss of US$0.56, alongside a net income loss of US$28.6 million, keeping profitability firmly in focus for investors. The company has seen quarterly revenue move from US$118.8 million in Q4 2024 to US$196.0 million in Q4 2025, while basic EPS has shifted from a loss of US$1.54 to a loss of US$0.56 over the same period. This frames a story where top line scale is running ahead of bottom line progress...